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BACKGROUND

COVID-19 Vaccine Formulations

Since the beginning of the Coronavirus Infectious Disease 2019 (COVID-19)
pandemic, through an unprecedented global effort at vaccine development, currently
we have several emergency use authorization (EUA) vaccines available and
administered in US and throughout the world. Three major vaccine platforms/
technologies utilized to develop the currently available and administered vaccines.
These platforms are: mRNA-based vaccines, viral vectored-based vaccines and
protein-based vaccines.
Usually, it takes about 10 years to complete research and development, clinical trial
and gain FDA approval for a typical vaccine. But COVID-19 vaccine development
broke all records, from the beginning through end everything have been accomplished
within a year. Therefore, although it may seemed rushed, every possible scientific
stringency, regulatory oversight and clinical safety have been closely monitored
leading to EUA of these vaccines.
In this presentation we will look into various COVID-19 vaccine platforms, immune
response and efficacy in clinical trial and vaccinated individuals with approval. We will
also analyze available information regarding vaccine efficacy/ protection against the
emergent COVID-19 variants of concern (VOC).

 mRNA-based: Moderna, Pfizer-BioNTech
 S-protein mRNA in lipid nanoparticle formulation
 Viral vector-based: genetically engineered virus with ‘S protein’ DNA
 Adenovirus: AstraZeneca, Johnson & Johnson ( J & J) , Gamaleya, CanSino
Biologics
 Protein-based vaccines:
 Novavax, PittcoVac -S protein specific


DNA vaccine


Inovio

 Killed virus vaccine
 Covaxin, Bharat Biotech, India

COVID-19 Vaccine Schedules

OBJECTIVES
The purpose of this presentation is to provide an overview of the various vaccines
formulations for coronavirus infectious disease 2019 (COVID-19). We will discuss
various technology platforms used for rapid development of the vaccines, types of
immune response generated, efficacy and vaccine-induced immune protection
particularly against the emerging variants.

Fig 2. SARS-CoV-2 Life Cycle and Structure
Important for Vaccine and Drug Development.
Fig 5. COVID-19 Vaccine Platforms.








Pfizer/BioNtech: 2 shots 21d apart, 95% protection
Moderna: 2 shots 28d apart, 94% protection
Johnson & Johnson: 1 shot, 85% efficacy against severe infection
AstraZeneca: 2 shots, 28d apart, ~70 (60-90)% efficacy
Sputnik V: 2-dose 28d apart, 95% efficacy
Covaxin-killed virus vaccine, Bharat Biotech & ICMR, 2 doses 14d apart

Safety and Efficacy of COVID-19 Vaccines

METHODS
COVID-19 related keyword search and review of primary and tertiary literatures
available in medRxiv, PubMed, CDC and NIAID database was employed. The search
specifically focused on Covid-19 vaccine clinical trial data and vaccine-induced
immune protection against infection.

Fig 3. The Trinity of COVID-19: Immunity,
Inflammation and Intervention
Fig 6. Relationship Between Vaccine Development, Vaccine
Acceptance and Infection

 All three vaccines Moderna, Pfizer and J & J are safe with minimum adverse
reactions
 Pfizer and Moderna vaccines work in population with 90% effective at preventing
infection, including asymptomatic infection
 These vaccines generated robust, neutralizing & long-lasting Ab lasting over >6
months, & protection could last up to 2 years
 These vaccines also generated T cell responses important in clearing of the virus
infection
 Pfizer Vaccine generated antibody response in pregnant and lactating women,
and well-tolerated
 Pfizer vaccine is also safe and effective in young adolescents
 Pfizer, J & J and Moderna vaccines are protective against the emerging variants
with varying degrees
 Both Pfizer and J & J vaccine effective against S. African and UK variant

CONCLUSION
 Several effective, and well-tolerated COVID-19 vaccines have been
developed in a record time.
 The vaccine technology platform ranges from lipid nanoparticle-mRNA,
adenoviral vector-mediated, protein vaccine and killed virus vaccine.
 All the vaccine formulations target ‘S’ protein, ligand for ACE2 receptor,
critically important for blocking the infection.
 Vaccines induced robust and protective immune responses in wide age
group individuals, and ethnicity.

EM of a cell heavily infected with SARSCOV-2 virus particles, isolated from a
patient sample. NIAID.

 Vaccines confer significant protection against both asymptomatic, and
severe infection, thus preventing hospitalization and death.
 Vaccine-induced immunity includes both B and T cell responses with
memory function for long-term protection.
 Early results indicate that these vaccines also confer significant
protection against the emerging variants.
 Even with available effective vaccines against COVID-19, ‘vaccine
hesitancy’ in US and around the world remains as a concern for
achieving ‘herd immunity’ for defeating the pandemic.
Fig 1. SARS-CoV-2 Structure, and Cell Infected with the Viral Particles.
Fig 4. COVID-19 Vaccine Development Timeline
Compared to Traditional Vaccines .

Fig 6. Proposed Mechanisms of Vaccineinduced Immune Response

